Stockreport

FDA grants IND clearance for Adicet Bio's renal cell carcinoma treatment trial [Yahoo! Finance]

Adicet Bio, Inc.  (ACET) 
Last adicet bio, inc. earnings: 5/3 05:00 pm Check Earnings Report
US:NASDAQ Investor Relations: aceto.com/ir/index.html
PDF a Phase I clinical trial of ADI-270 for relapsed or refractory renal cell carcinoma (r/r RCC). ADI-270 is an armoured allogeneic 'off-the-shelf' gamma delta chimeric a [Read more]